CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The approval of ipilimumab for the treatment of melanoma is a major step forward in cancer immunotherapy. The randomized Phase II trials yielded improvement in irPFS in both small-cell lung cancer and non-squamous-cell lung cancer patients treated with two cycles of chemotherapy followed by chemotherapy combined with ipilimumab. Ipilimumab is currently being evaluated for the treatment of squamous-cell lung cancer and small-cell lung cancer.

Original languageEnglish (US)
Title of host publicationTargeted Therapies for Non-Small-Cell Lung Cancer
PublisherFuture Medicine Ltd.
Pages47-54
Number of pages8
ISBN (Electronic)9781780840468
ISBN (Print)9781780841236
DOIs
StatePublished - Oct 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC'. Together they form a unique fingerprint.

Cite this